Myocardial contrast echocardiography: cardiovascular effects of the contrast medium SHU 454 in dogs.
SHU 454 (Schering AG, Berlin, Federal Republic of Germany) is a new contrast agent that releases microbubbles with a median diameter of 3 microns into the circulation. During echocardiography, it permits visualization of myocardial blood flow (MBF) when given by intracoronary or aortic root injections. Its hemodynamic effects were investigated in anesthetized dogs with a view to application in humans. Cardiac effects were studied after intracoronary injections of 1 mL of SHU 454 (100 mg/mL). Twenty seconds after injection, MBF increased 35% and coronary vascular resistance decreased accordingly. The increase in MBF was not seen when the coronary bed was maximally dilated with intravenous dipyridamole. Peripheral effects were evaluated after 5 mL of SHU 454 (200 mg/mL) was injected into the aortic root, which gave the same myocardial echo contrast. Aortic pressure decreased 5%, and heart rate and dP/dt increased. To evaluate the effects of hypertonicity, SHU 454 was compared with five radiocontrast media and glucose. Its effects on MBF were similar to those of radiologic contrast media on an equal volume basis. Only 1 mL of intracoronary SHU 454, however, was required for myocardial contrast enhancement. The results suggest that visualization of the myocardium using SHU 454 or similar compounds for contrast echocardiography is a viable prospect.
Heidelmeyer
C F
CF
Department of Anaesthesia, AG Kreislaufforschung, Freie Universitaet Berlin, Federal Republic of Germany.
Brueckner
J B
JB
Schartl
M
M
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002496:Central Venous Pressure / Q000187:drug effects; D003287:Contrast Media / Q000494:pharmacology*; D003326:Coronary Circulation / Q000187:drug effects*; D003974:Diatrizoate Meglumine / Q000494:pharmacology; D004285:Dogs; D004452:Echocardiography / Q000379:methods; D005260:Female; D005947:Glucose / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006982:Hypertonic Solutions / Q000494:pharmacology; D007472:Iohexol / Q000031:analogs & derivatives / Q000494:pharmacology; D007482:Iothalamate Meglumine / Q000494:pharmacology; D008297:Male; D009994:Osmolar Concentration; D011134:Polysaccharides / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects
D003287:Contrast Media; D006982:Hypertonic Solutions; D011134:Polysaccharides; D003974:Diatrizoate Meglumine; D007472:Iohexol; C001694:meglumine ioxithalamate; C038192:iopromide; C040642:SHU 454; D005947:Glucose; D007482:Iothalamate Meglumine